Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | F10 | P00742 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434675 | 1.00 | ADAM17 (0.37) | ADAM17PLAUGAAF10F2 | |
| SCHEMBL7378281 | 1.00 | ADAM17 (0.37) | ADAM17PLAUGAAF10F2 | |
| Hydrochloric Acid SCHEMBL6433470 | 0.99 | ADAM17 (0.36) | ADAM17PLAUGAAF10F2 | |
| SCHEMBL7373053 | 0.84 | ALDH1A1 (0.45) | PLAULMNAALDH1A1TDP1 | |
| SCHEMBL7590429 | 0.84 | ALDH1A1 (0.45) | PLAULMNAALDH1A1TDP1 | |
| SCHEMBL6433528 | 0.84 | ALDH1A1 (0.45) | PLAULMNAALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL6434299 | 0.83 | ALDH1A1 (0.44) | PLAULMNAALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL6433791 | 0.83 | ALDH1A1 (0.44) | PLAULMNAALDH1A1TDP1 | |
| SCHEMBL7378285 | 0.80 | PLAU (0.38) | ADAM17PLAUGAAITGB1ITGA4 | |
| SCHEMBL7370376 | 0.78 | PLAU (0.53) | PLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | ADAM17 26/4885PLAU 119/4885GAA 1575/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | ADAM17 26/4885PLAU 119/4885GAA 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.